Literature DB >> 85106

Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound.

J Vermylen, D A Chamone, M Verstraete.   

Abstract

Ingestion of 1.2 g Bay g 6575 daily for 1 week by six healthy volunteers had no effect on blood-coagulation, fibrinolysis, or platelet aggregation in vitro, but it seemed to inhibit platelet aggregation in vivo (shown by a smaller reduction in the platelet aggregate ratio after venous occlusion). Plasma drawn from five volunteers after ingestion of a single dose of 1.2 g of the drug stimulated prostacyclin release from slices of rat aorta which had been washed until they stopped releasing anti-aggregating substances, whereas plasma from the same individuals before ingestion of the substance did not. Administration of either Bay g 6575 or dipyridamole alone had no effect on platelet aggregation in vitro, but combined administration resulted in a striking and prolonged inhibition of A.D.P.-induced platelet aggregation. It is proposed that the previously described antithrombotic properties of Bay g 6575 in animals are due to stimulation of prostacyclin release from the vessel wall, and that this effect is also demonstrable in man.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 85106     DOI: 10.1016/s0140-6736(79)90944-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  16 in total

1.  [Prevalence of plasma factor deficiency in the Vienna population. Results of a screening study of 1,300 adults].

Authors:  H Sinzinger; J Flores; F Rauscha
Journal:  Klin Wochenschr       Date:  1988-09-01

Review 2.  Introduction: thromboxane in biological systems and the possible impact of its inhibition.

Authors:  M Verstraete
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Nafazatrom: in-vitro assessment of radiation and drug activity against animal and human cell lines.

Authors:  J S Haas; C D Haas; G W Kyle
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Phase I and pharmacologic evaluation of nafazatrom in patients with cancer.

Authors:  C D Haas; L H Baker; L J Evans
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 5.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

6.  Effect of nafazatrom and indomethacin on pulmonary removal of prostaglandin E1 after endotoxin in rabbits.

Authors:  C N Gillis; A M Havill; R Moalli
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

7.  Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.

Authors:  C D Haas; G W Kyle; J D Crissman; M F Schaldenbrand
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  Pharmacological control of leukotriene and prostaglandin production from mouse peritoneal macrophages.

Authors:  K Brune; U Aehringhaus; B A Peskar
Journal:  Agents Actions       Date:  1984-06

Review 9.  Prostaglandin I2 (prostacyclin).

Authors:  J G Kelton; M A Blajchman
Journal:  Can Med Assoc J       Date:  1980-01-26       Impact factor: 8.262

10.  Phase I clinical study of nafazatrom.

Authors:  G N Hortobagyi; N E Papadoupoulos; D Frye; J Ajani; J M Reuben
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.